|Mr. Fredericus A. Colen||Pres & CEO||N/A||N/A||1953|
|Mr. Christopher Clark BA (Honours), PgD, CA||CFO & Corp. Sec.||276.95k||N/A||1972|
|Ms. Vicki Bebeau||VP of Clinical & Regulatory Affairs||277.93k||N/A||1951|
|Mr. Randy Lane||VP of New Concept Devel. & Intellectual Property||225.33k||N/A||1973|
|Mr. Alexei J. Marko||Advisor & Director||340.04k||N/A||1969|
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Neovasc Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.